anaesthetic & critical care studies summaries

---

Protocol v28.0 30/06/2025
​Rotherham Principal Investigator: Professor Anil Hormis
Research team member: Dr Katie Webb
​

research topic:

Dexamethasone in community acquired pnuemonia. 

trial groups:

Intervention: 6mg dexamethasone for 10 days or until discharged, whichever is soonest
Control: Usual care

inclusion criteria:

• >18 years old, hospitilised with Community-acquired pneumonia (CAP) with planned antibiotic treatment (excluding patients with suspected or confirmed SARS-CoV-2, influenza, active pulmonary tuberculosis or Pneumocystis jirovecii pneumonia) - symptoms of LRTI and radiological evidence
•  No medical history that might, in the opinion of the attending clinician, put the patient at significant risk if he/she were to participate in the trial

exclusion criteria:

• Condition explained by alternative diagnoses e.g. heart failure
• Pregnancy and breast feeding
• Consideration of important side effects e.g. risk of hyperglycaemia (QDS BMs), peptic ulceration, psychiatric reactions, fluid retention, risk of adrenal insufficiency
• Confirmed COVID, influenza, PCP, active TB

consent:

​Formal consent is required for RECOVERY trial enrolment/randomisation.
​If you think your patient is in any way eligible please contact the research team who will review the full inclusion/exclusion criteria and approach for consent.